Correlation Engine 2.0
Clear Search sequence regions


  • A3AR (7)
  • chronic pain (1)
  • Gαi3 (2)
  • ligand (1)
  • neurons (1)
  • receptor (1)
  • spinal cord (1)
  • Sizes of these terms reflect their relevance to your search.

    The A3 adenosine receptor (A3AR) is a promising therapeutic target for inflammatory diseases, cancer, and chronic neuropathic pain, with agonists already in advanced clinical trials. Here we report an in-depth comparison of the pharmacological properties and structure-activity relationships of existing and expanded compound libraries of 2-substituted 1H-imidazo[4,5-c]quinolin-4-amine and 4-amino-substituted quinoline derivatives that function as A3AR positive allosteric modulators (PAMs). We also show that our lead compound from each series enhances adenosine-induced A3AR signaling preferentially toward activation of Gαi3 and GαoA isoproteins, which are coexpressed with the A3AR in immune cells and spinal cord neurons. Finally, utilizing an extracellular/intracellular chimeric A3AR approach composed of sequences from a responding (human) and a nonresponding (mouse) species, we provide evidence in support of the idea that the imidazoquinolin-4-amine class of PAMs variably interacts dually with the orthosteric ligand binding site as well as with a separate allosteric site located within the inner/intracellular regions of the receptor. This study has advanced both structural and pharmacological understanding of these two classes of A3AR PAMs, which includes leads for future pharmaceutical development. © 2022 American Chemical Society.

    Citation

    Courtney L Fisher, Lucas B Fallot, Tina C Wan, Robert F Keyes, R Rama Suresh, Amy C Rothwell, Zhan-Guo Gao, John D McCorvy, Brian C Smith, Kenneth A Jacobson, John A Auchampach. Characterization of Dual-Acting A3 Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gαi3 and GαoA Isoprotein Activation. ACS pharmacology & translational science. 2022 Aug 12;5(8):625-641


    PMID: 35983277

    View Full Text